register

News & Trends - Pharmaceuticals

Medicines not mammograms are behind the reduction in breast cancer deaths

Health Industry Hub | June 29, 2020 |

Pharma News: A new Australian systemic review questioned whether population-based mammographic screening or endocrine therapy and chemotherapy (adjuvant therapy) after curative surgery for early or operable breast cancer were associated with the decline in breast cancer mortality.

The decline is breast cancer deaths in the last 20 years can be attributed to the use of therapies such as tamoxifen and chemotherapy, and not to the mammogram screening program, according to an analysis of Victorian women.

The study found that the mammogram screening program did not result in more breast cancer in Victoria being detected at an early rather than an advanced stage, so there was no population mortality benefit. Crude breast cancer mortality declined by 30% after 1994 and the researchers say this was all linked to adjuvant and chemotherapy therapy uptake and not screening.

The authors conclude that BreastScreen should be ceased as persistence with the program may continue to expose women to unnecessary morbidity and mortality.


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.